SOPHiA GENETICS officer sells 3 shares for taxes

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert had 3 Ordinary Shares sold in the open market at $4.71 per share.

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert had 3 Ordinary Shares sold in the open market at $4.71 per share. According to the disclosure, the sale was a “sell to cover” transaction to satisfy tax obligations from restricted stock units that vested on March 30, 2026, and was not a discretionary trade. Following this small tax-related sale, he holds 92,383 Ordinary Shares directly.

Insider Trade Summary

Net Seller: 3 shares

Net Sell 1 txn

Insider Puylaert Kevin

Role Chief Sales Officer

Sold 3 shs ($14.13)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	3	$4.71	$14.13

Holdings After Transaction: Ordinary Shares — 92,383 shares (Direct)

Footnotes (1)

1. F1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on March 30, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades.

Key Figures

Shares sold: 3 shares Sale price per share: $4.71 per share Shares held after transaction: 92,383 shares +1 more

4 metrics

Shares sold 3 shares Open-market sale on March 31, 2026

Sale price per share $4.71 per share Ordinary Shares sold to cover taxes

Shares held after transaction 92,383 shares Direct ownership following the tax-related sale

RSU vesting date March 30, 2026 Vesting that created the tax obligation

Key Terms

sell to cover, restricted stock units, open market, Ordinary Shares

4 terms

sell to cover financial

"The sales were effected as a "sell to cover" transaction and do not represent discretionary trades."

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

restricted stock units financial

"to satisfy tax obligations in connection with the vesting of restricted stock units on March 30, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

open market financial

"Represents shares sold by the Reporting Person in the open market to satisfy tax obligations"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

Ordinary Shares financial

"security_title": "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SOPHiA GENETICS (SOPH) executive Kevin Puylaert report in this Form 4?

He reported a small tax-related share sale. 3 Ordinary Shares were sold in the open market at $4.71 each to cover tax obligations from restricted stock units that vested on March 30, 2026.

How many SOPHiA GENETICS (SOPH) shares did the officer sell and at what price?

3 Ordinary Shares were sold. The disclosed sale price was $4.71 per share in an open-market transaction described as a “sell to cover,” used to satisfy tax obligations tied to restricted stock unit vesting.

Was the SOPHiA GENETICS (SOPH) insider share sale a discretionary trade?

No, it was not a discretionary trade. The filing states the sale was effected as a “sell to cover” solely to satisfy tax obligations related to restricted stock units vesting, rather than a voluntary decision to reduce holdings.

How many SOPHiA GENETICS (SOPH) shares does Kevin Puylaert hold after this transaction?

He holds 92,383 Ordinary Shares after the transaction. This figure reflects his direct ownership following the 3-share tax-related sale, showing that the reported sale was very small relative to his remaining position.

What triggered the tax obligations behind the SOPHiA GENETICS (SOPH) sell-to-cover transaction?

Tax obligations arose from restricted stock units vesting on March 30, 2026. To meet these obligations, 3 Ordinary Shares were sold the next day in an open-market sell-to-cover transaction, as disclosed in the Form 4 footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 10:41 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Puylaert Kevin

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Sales Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/31/2026		S		3(1)	D	$4.71	92,383	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on March 30, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Kevin Puylaert	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)